Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 10/20 | 0.37 |
| ▸ | JAK1 | P23458 | 10/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354136 | 0.93 | PKM (0.37) | CHEK2GPR119NPC1RAB9AJAK2 | |
| SCHEMBL355334 | 0.92 | HDAC1 (0.41) | NPC1RAB9AHRH3WNT3A | |
| SCHEMBL15981203 | 0.87 | SYK (0.38) | NPC1RAB9A | |
| SCHEMBL353867 | 0.82 | HDAC8 (0.39) | — | |
| SCHEMBL355578 | 0.80 | NPC1 (0.49) | NPC1RAB9AWNT3A | |
| SCHEMBL353174 | 0.80 | SYK (0.42) | HRH3 | |
| SCHEMBL353421 | 0.79 | FGFR1 (0.40) | — | |
| SCHEMBL356031 | 0.79 | HRH3 (0.39) | HRH3 | |
| SCHEMBL353143 | 0.79 | HDAC8 (0.39) | HRH3 | |
| SCHEMBL355960 | 0.79 | FGFR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CHEK2 3205/4885GPR119 926/4885NPC1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.